Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (271)
Related Products (271)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
Civorebrutinib
0 ImagesCat. No.: HY-111781CAS No.: 2155853-43-1Synonyms: WS-413Civorebrutinib (WS-413) is a selective, orally active BTK and TEC inhibitor with an IC50 of <100 nM for both targets. Civorebrutinib inhibits B cell activation. Civorebrutinib significantly suppresses the in vivo growth of diffuse large B-cell lymphoma cells. Civorebrutinib can be used for the research of diffuse large B-cell lymphoma.
-
BTK-IN-5
0 ImagesCat. No.: HY-115876CAS No.: 2145152-06-1BTK-IN-5 is a covalent BTK inhibitor for researching medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.
-
CFON-026
0 ImagesCat. No.: HY-174850CAS No.: 2941611-57-8CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27 nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia.
-
TM471-1
0 ImagesCat. No.: HY-174129CAS No.: 2649008-95-5
-
BMS-986143
0 ImagesCat. No.: HY-145373CAS No.: 1643372-83-1
-
G-744
0 ImagesCat. No.: HY-102036CAS No.: 1346669-54-2
-
DFCI-002-06
0 ImagesCat. No.: HY-181050CAS No.: 3092208-36-8DFCI-002-06 is an orally active dual-target HCK/BTK PROTAC degrader with DC₅₀ values for HCK and BTK of 1.3 and 4.5 nM respectively. DFCI-002-06 retains higher anti-tumor activity than the HCK/BTK dual-target inhibitor (HY-15805), inducing apoptosis in cancer cells. DFCI-002-06 can be used for the study of MYD88 mutant B-cell malignancies.
-
Cinsebrutinib
0 ImagesCat. No.: HY-156604CAS No.: 2724962-58-5Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). Cinsebrutinib has the potential for cancer study.
-
CHMFL-BTK-01
0 ImagesCat. No.: HY-101521CAS No.: 2095280-64-9
-
BTK-IN-14
0 ImagesCat. No.: HY-147584CAS No.: 2764674-60-2BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1).
-
BTK-IN-20
0 ImagesCat. No.: HY-148832CAS No.: 1581714-50-2
-
BTK-IN-27
0 ImagesCat. No.: HY-156553CAS No.: 1841502-36-0
-
BTK-IN-11
0 ImagesCat. No.: HY-147581CAS No.: 2765852-46-6BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2).
-
JAK3/BTK-IN-3
0 ImagesCat. No.: HY-143718CAS No.: 2674036-98-5JAK3/BTK-IN-3 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)
-
CA/PRAK-IN-1
0 ImagesCat. No.: HY-184792CA/PRAK-IN-1 is a dual inhibitor of carbonic anhydrase (Carbonic Anhydrase) and PRAK, with a Ki of 20.1 nM against hCA IX and 16.4 nM against hCA XII. CA/PRAK-IN-1 exhibits inhibitory activity against YES1 kinase, BTK, and MAP4K3. CA/PRAK-IN-1 induces G0/G1 phase arrest of the cancer cell cycle, inhibits DNA synthesis, disrupts hypoxia-driven survival pathways, promotes cell death, and shows broad-spectrum cytotoxicity against tumor cells. CA/PRAK-IN-1 can be used in research on various cancers including leukemia, colon cancer, melanoma, and renal cancer.
-
GSTO1-IN-2
0 ImagesCat. No.: HY-161876CAS No.: 3020776-77-3GSTO1-IN-2 (Compound B-9) is a dual covalent inhibitor of GSTO1/BTK with IC50 values of 441 nM and 6.2 nM respectively.
